Seagen Overview

  • Year Founded
  • 1998

Year Founded

  • Status
  • Acquired/​Merged

  • Employees
  • 4,000

Employees

  • Latest Deal Type
  • M&A

  • Latest Deal Amount
  • $43.4B

Seagen General Information

Description

Developer of cancer therapies and drugs focused on treating Hodgkin lymphoma, non-Hodgkin lymphoma, urothelial cancer and breast cancer. The company specializes in antibody-drug conjugates, conjugation chemistry, monoclonal antibody-based therapies for cancer, cancer drug development, drug development, blood cancers, bladder cancer, Hodgkin lymphoma, and non-Hodgkin lymphoma

Contact Information

Website
www.seagen.com
Formerly Known As
Seattle Genetics, Seattle Genetics Inc
Ownership Status
Acquired/Merged
(Operating Subsidiary)
Financing Status
Formerly VC-backed
Corporate Office
  • 21823 30th Drive Southeast
  • Building 3
  • Bothell, WA 98021
  • United States
+1 (425)
Primary Industry
Drug Discovery
Other Industries
Pharmaceuticals
Biotechnology
Parent Company
Pfizer (Pharmaceuticals)
Vertical(s)
Life Sciences, Oncology
Corporate Office
  • 21823 30th Drive Southeast
  • Building 3
  • Bothell, WA 98021
  • United States
+1 (425)

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Seagen Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
9. Merger/Acquisition 14-Dec-2023 $43.4B Completed Generating Revenue
8. PIPE 14-Sep-2020 Completed Generating Revenue
7. Secondary Transaction - Open Market Completed Generating Revenue
6. PIPE 17-Jan-2014 Completed Profitable
5. 2PO 03-Feb-2011 Completed Profitable
4. PIPE 02-Jul-2003 Completed Profitable
3. IPO 07-Mar-2001 Completed Profitable
2. Early Stage VC (Series B) 15-Mar-2000 $30M $36.2M Completed Profitable
1. Early Stage VC (Series A) 01-Mar-1998 $6.25M $6.25M Completed Product Development
To view Seagen’s complete valuation and funding history, request access »

Seagen Cap Table

Stock # of Shares
Authorized		 Par Value Dividend Rate (%) Original
Issue Price		 Liquidation Liquidation
Pref. Multiple		 Conversion Price % Owned
Series B
Series A
To view Seagen’s complete cap table history, request access »

Seagen Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Developer of cancer therapies and drugs focused on treating Hodgkin lymphoma, non-Hodgkin lymphoma, urothelial cancer an
Drug Discovery
Bothell, WA
4,000 As of 2024

Alameda, CA
 

San Carlos, CA
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Seagen Competitors (47)

One of Seagen’s 47 competitors is Exelixis, a Formerly VC-backed company based in Alameda, CA.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Exelixis Formerly VC-backed Alameda, CA
Iovance Biotherapeutics Corporation San Carlos, CA
Regeneron Pharmaceuticals Formerly VC-backed Tarrytown, NY
Sutro Biopharma Formerly VC-backed South San Francisco, CA
MorphoSys Formerly PE-Backed Planegg, Germany
You’re viewing 5 of 47 competitors. Get the full list »

Seagen Patents

  • 1,763

    Total Documents Applications and Grants

  • Total Patents Families

  • 920

    Granted

  • 461

    Pending

  • Expiring in next 12 mo

Seagen Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
US-20240226313-A1 Ceacam5 antibody-drug conjugates and methods of use thereof Inactive 17-Nov-2022
EP-4321522-A1 Cytotoxic compounds and conjugates thereof Pending 12-Aug-2022
US-20240123080-A1 Cytotoxic compounds and conjugates thereof Pending 12-Aug-2022
US-20230381321-A1 Camptothecin conjugates Pending 17-Mar-2022
AU-2023234594-A1 Camptothecin conjugates Pending 17-Mar-2022 A61K47/545
To view Seagen’s complete patent history, request access »

Seagen Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Seagen Former Investors (11)

Investor Name Investor Type Holding Investor Since Participating Rounds
Cascade Investment Family Office Minority
Delphi Ventures Venture Capital Minority
Indosuez Ventures Venture Capital Minority
Merck & Co. Corporation Majority
New Enterprise Associates Venture Capital Minority
You’re viewing 5 of 11 investors. Get the full list »

Seagen Investments & Acquisitions (6)

Seagen’s most recent deal was a Later Stage VC with Abacus Bioscience for . The deal was made on 07-Feb-2023.

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
Abacus Bioscience 07-Feb-2023 Later Stage VC Drug Discovery
Pieris Pharmaceuticals 24-Mar-2021 PIPE Drug Discovery
Cascadian Therapeutics 09-Mar-2018 Merger/Acquisition Biotechnology
Bristol-Myers Squibb (biotech manufacturing plant in Bothell) 01-Oct-2017 Corporate Asset Purchase Buildings and Property
Monte Villa Parkway Research Center 01-Aug-2017 Merger/Acquisition Laboratory Services (Healthcare)
You’re viewing 5 of 6 investments and acquisitions. Get the full list »

Ready to get started?

Request a free trial

Seagen ESG

Risk Overview

Risk Rating

Updated November, 08, 2024

24.58 | Med Risk

Risk Scale

A lower score indicates better sustainability

Negl

0-10

Low

10-20

Med

20-30

High

30-40

Severe

40+

Exposure

Exposure refers to the extent to which a company is exposed to different material ESG issues

Management

Management is related to actions taken to manage ESG issues

Peers Analysis

Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.

Global

Covered Companies

of 15,100

Rank

Percentile

Pharmaceuticals

Industry

of 851

Rank

Percentile

Biotechnology

Subindustry

of 367

Rank

Percentile

To view Seagen’s complete esg history, request access »

Seagen FAQs

  • When was Seagen founded?

    Seagen was founded in 1998.

  • Where is Seagen headquartered?

    Seagen is headquartered in Bothell, WA.

  • What is the size of Seagen?

    Seagen has 4,000 total employees.

  • What industry is Seagen in?

    Seagen’s primary industry is Drug Discovery.

  • Is Seagen a private or public company?

    Seagen is a Private company.

  • What is the current valuation of Seagen?

    The current valuation of Seagen is .

  • What is Seagen’s current revenue?

    The current revenue for Seagen is .

  • How much funding has Seagen raised over time?

    Seagen has raised $1.29B.

  • Who are Seagen’s investors?

    Cascade Investment, Delphi Ventures, Indosuez Ventures, Merck & Co., and New Enterprise Associates are 5 of 11 investors who have invested in Seagen.

  • Who are Seagen’s competitors?

    Exelixis, Iovance Biotherapeutics, Regeneron Pharmaceuticals, Sutro Biopharma, and MorphoSys are some of the 47 competitors of Seagen.

  • When was Seagen acquired?

    Seagen was acquired on 14-Dec-2023.

  • Who acquired Seagen?

    Seagen was acquired by Pfizer (Pharmaceuticals).

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read blog »

  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process »